Navigation Links
Genzyme Announces First Phase III Study of Tolevamer in Diarrhea Patients

Genzyme Corp. announced top-line data from the first of two Phase 3 clinical studies to assess the safety and efficacy of tolevamer liquid, an investigational, non-antibiotic , polymer therapy for patients with Clostridium difficile associated diarrhea (CDAD). The second Phase 3 study of tolevamer liquid is fully enrolled and results are expected later this year.

In this first Phase 3 study known as the Polymer Alternative for CDAD Treatment (PACT) study, tolevamer liquid did not meet its primary endpoint of non-inferiority to the standard prescribed oral dose of the antibiotic vancomycin, as measured by the percent of patients with resolution of CDAD. This result contrasts with the findings from Genzyme's earlier Phase 2 study of a solid oral dosage formulation of tolevamer that met its primary endpoint of non-inferiority compared to vancomycin.

Consistent with recent published studies, high rates of CDAD recurrences were observed in patients treated with either vancomycin or metronidazole. High CDAD recurrence rates were not observed in patients treated with tolevamer liquid. Tolevamer liquid was generally well tolerated with no unanticipated safety concerns. Data from this first Phase 3 study is expected to be presented at a future medical conference.

"These are disappointing results that alter our expectations about the potential for commercializing tolevamer in the near future," stated Henri A. Termeer, chairman and chief executive officer of Genzyme Corp. "The results of our second Phase 3 study will be available later this year and will help us determine what contribution tolevamer might be able to make in addressing this serious unmet medical need."

C. difficile has become one of the most significant infection control concerns in healthcare today. Physicians worldwide are confronting a worsening epidemic, with an alarming rise in the incidence of disease, higher numbers of patients with complications and
'"/>




Page: 1 2

Related medicine news :

1. Ramdoss Announces Introduction of RCH-II
2. Britain Announces Third Transfusion Related Mad Cow Case
3. Tibet Announces the Dalai Lama’s Tour of South Americ
4. Indian PM Announces Of Setting Up India Study Center At Tashkent
5. PowderMed Announces Needle-Less Flu Vaccine
6. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
7. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
8. Australian Government Announces Survey To Tackle Childhood Obesity
9. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
10. Apollo Announces Research on Indian Cardiac Epidemic
11. Government Announces Steps To Promote Ayurvedic Medicine
Post Your Comments:
(Date:12/26/2014)... Angeles, CA (PRWEB) December 26, 2014 ... power score of 3.1 out of 5. This score ... a low level of product specialization, low switching costs ... power is reduced by the low availability of substitutes ... the world price of steel and aluminum, key inputs ...
(Date:12/26/2014)... 2014 “Many people become overwhelmed by ... claim issues and phone calls with insurance companies,” The ... featuring their free eBook on pedestrian and bicycle ... pedestrian and bicycle auto accident claims assures the injured ... of professionally handling their case while they focus on ...
(Date:12/26/2014)... Phoenix, AZ (PRWEB) December 26, 2014 ... dependable source for the best in heating, cooling ... demand for 24 hour emergency services in 2014 ... customers alike know that Arizona is known for ... contractor company that understands the intricacies and details ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) – ... the current treatment landscape, unmet needs, current pipeline ... Stivarga is a drug which is used in ... Ingelheim is developing nintedanib (BIBF-1120), an orally available ... in the US, Europe, and Japan. The drug ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of ... its new selection of black one-shoulder cocktail dresses . ... they are available at discounted prices, up to 70% off. ... last for three weeks only. You know, we have thousands ... interested in our new items can visit our website for ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... N.J., Dec. 3 Covance Inc. (NYSE:,CVD), a ... leading,humanitarian organization, announced today that they are partnering ... for,Orphans and Vulnerable Children in Rwanda. Covance will ... day care centers for,children ages two to four ...
... protect cells from the powerful, common chemotherapeutic agent doxorubicin ... the drug also can destroy the heart., We found ... cell survival in the face of doxorubicin, says Dr. ... Georgia Cancer Center. At the moment you start inactivating ...
... debate , MONDAY, Dec. 3 (HealthDay News) -- There,s ... the risk of developing multiple sclerosis (MS) in childhood, a ... investigated a possible association between the hepatitis B vaccine and ... short- or long-term risk of MS. However, the studies ...
... HARBOR, N.Y. (Mon., Dec. 3, 2007) Two ... early embryogenesis are featured in this months release of ... which are freely accessible online ( www.cshprotocols.org ), describe ... These cell-tagging techniques, combined with sophisticated imaging methods, ...
... As momentum continues to,build on the issue of ... the Pharmaceutical Care Management Association,(PCMA) today announced a ... Ph.D., Sc.D., Last year, Dr. Bootman co-chaired ... all physicians begin using e-prescribing by,2010 to help ...
... and HUNTSVILLE, Ala., Dec. 3 Operon,Biotechnologies, Eurofins ... the,Eurofins Genomics network - announced today that they ... a new worldwide leader in the competitive,custom oligonucleotide ... state of,the art high-throughput production facilities in all ...
Cached Medicine News:Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 2Health News:Covance and Care Partner on Rwanda Early Childhood Development Initiative 3Health News:Genes identified that protect against heart damage from chemotherapy 2Health News:No Link Between Hepatitis B Shot, MS: Study 2Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:MWG and Operon Are Joining Forces 2
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced ... medical device manufacturer BMC Medical Co., Ltd. ... listed below infringe ResMed,s patents, and entered an order prohibiting ... the United States : , iVolve ... Willow nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... VIEW, Calif., Sept. 16 Based on its recent ... market, Frost & Sullivan recognizes Accelrys, Inc., with the ... Product Innovation of the Year. The company has merited ... a solution that provides, for the first time, a ...
... (LIG) (Pink Sheets: LIGA ), a Dallas-based ... cleaner and disinfectant for the masks of CPAP (continuous ... for patients suffering from sleep apnea. The ... by Jones Products Company, LLC, which is 51% owned ...
Cached Medicine Technology:Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 2Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 3Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution 4LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 2LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner 3
... new Finnpipette Focus from Thermo ... combine ergonomics with uncompromising performance. ... plate offers a custom fit ... new shorter tip cones allow ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Inquire...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
Medicine Products: